Holen Sie sich die Stockscreener-App
2.44
1.21%
-0.03
Handel nachbörslich:
2.52
0.08
+3.28%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ESPR?
Forum
Prognose
Aktiensplit
Esperion Therapeutics Inc Aktie (ESPR) Neueste Nachrichten
Esperion outlines Vision 2040 with Corstasis acquisition and targets 2026 operating expenses up to $255M while expanding cardiometabolic portfolio - MSN
FTAI Aviation To Rally More Than 43%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
Citizens raises Esperion Therapeutics price target on drug growth By Investing.com - Investing.com Canada
Equities Analysts Issue Forecasts for ESPR Q1 Earnings - MarketBeat
Esperion Stock Pre-Market (-0.1%): EPS Miss Mutes Revenue Beat & Acquisition News - Trefis
ESPR's Q4 Earnings Lag Estimates, Revenues Beat, Stock Down - Yahoo Finance
Esperion at Citizens Life Sciences: Strategic Growth and Acquisition - Investing.com
What is HC Wainwright's Estimate for ESPR Q4 Earnings? - MarketBeat
Esperion Therapeutics (ESPR) Turns Q4 Profit As Bears Question Trailing Losses And Balance Sheet - Sahm
H.C. Wainwright Maintains Buy on Esperion Therapeutics (ESPR) March 2026 - Meyka
Esperion Therapeutics, Inc (ESPR) Misses Q4 EPS Estimates - AlphaStreet
Esperion shares rise 8% after revenue tops forecasts and acquisition announced - MSN
Esperion Therapeutics (NASDAQ:ESPR) Stock Price Down 5.1%Time to Sell? - MarketBeat
ESPR Stock Falls After Esperion’s Mixed Q4 — Retail Remains Unfazed, Eyes ‘Massive’ Upcoming Catalysts - Stocktwits
Esperion Therapeutics Reports Strong 2025 Revenue Growth, Expands Global Cardiovascular Franchise and Advances New Therapies - Minichart
Esperion Therapeutics, Inc (ESPR) Reports Q4 Earnings - AlphaStreet
Esperion Therapeutics Q4 Earnings Call Highlights - Yahoo Finance
Esperion Q4 2025 slides: 38% sales growth, $4.6B CHF opportunity - Investing.com Nigeria
ESPR: Record revenue growth and strategic expansion set the stage for sustained momentum in 2026 - TradingView
Earnings call transcript: Esperion Therapeutics Q4 2025 misses EPS but sees revenue surge - Investing.com Canada
Esperion Therapeutics, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:ESPR) 2026-03-10 - Seeking Alpha
Esperion shares jump 8% on revenue beat, acquisition plans - Investing.com
Esperion Therapeutics (NASDAQ:ESPR) Posts Quarterly Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
Esperion Q4 2025 Earnings: $61.8M Profit, $168.4M Revenue Exceeds EstimatesNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Esperion Therapeutics (ESPR) Misses Q4 Earnings Estimates - Yahoo Finance
Esperion Therapeutics Swings to Q4 Earnings, Revenue Rises - marketscreener.com
Earnings Flash (ESPR) Esperion Therapeutics Posts Q4 EPS $0.22, vs. FactSet Est of $0.27 - marketscreener.com
ESPERION THERAPEUTICS ($ESPR) Releases Q4 2025 Earnings - Quiver Quantitative
Esperion Therapeutics: Fourth Quarter Earnings Overview - Bitget
Esperion Therapeutics: Q4 Earnings Snapshot - Barchart.com
Esperion Therapeutics Q4 revenue jumps 144% on US product strength - TradingView
Esperion Reports 21% Revenue Growth in FY25, Announces Strategic Acquisition of Corstasis Therapeutics - Quiver Quantitative
Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - The Manila Times
Esperion Therapeutics (NASDAQ:ESPR) Trading Up 9.2%What's Next? - MarketBeat
Esperion Therapeutics Q4 2025 earnings preview - MSN
United StatesArnold & Porter Advises Corstasis In Sale To Esperion - Mondaq
A Peek at Esperion Therapeutics's Future Earnings - Benzinga
Market Rankings: Can Esperion Therapeutics Inc outperform under higher oil pricesPortfolio Growth Summary & Low Drawdown Investment Strategies - baoquankhu1.vn
Esperion settles litigation with Accord Healthcare - MSN
Weekly Buzz: TBPH Cuts Jobs, ASND Gets FDA Nod, AARD Puts HERO On Hold, ESPR Opens Wallet - RTTNews
/C O R R E C T I O N -- HLS Therapeutics Inc./ - Yahoo Finance
Royce & Associates LP Takes Position in Esperion Therapeutics, Inc. $ESPR - MarketBeat
ESPR to Boost Cardiovascular Portfolio With Corstasis Buyout for $75M - The Globe and Mail
Esperion Therapeutics Hits Day Low of $2.83 Amid Price Pressure - Markets Mojo
electroCore, Inc. (ECOR) May Report Negative Earnings: Know the Trend Ahead of Q4 Release - Finviz
Esperion Therapeutics Inc (ESPR) Strengthens Business Outlook Amid Strategic Agreements - Finviz
Esperion to acquire Corstasis for cardiovascular franchise expansion - Pharmaceutical Technology
Esperion Therapeutics: $75 Million Acquisition Of Corstasis To Expand Cardiovascular Franchise With Enbumyst Nasal Spray - Pulse 2.0
Deal Watch: Esperion Augments Cardiovascular Franchise Via Corstasis Buyout - Citeline News & Insights
Esperion Therapeutics (NASDAQ:ESPR) Shares Down 13.1%Should You Sell? - MarketBeat
Ann Arbor pharmaceutical company to pay $75M in deal for new drug - Crain's Detroit Business
Esperion Therapeutics (NASDAQ:ESPR) Given New $5.00 Price Target at Needham & Company LLC - MarketBeat
Esperion to acquire Corstasis Therapeutics - The Pharma Letter
Esperion to acquire Enbumyst maker for $75M plus milestones - Investing.com Nigeria
Esperion Acquires Enbumyst Maker Corstasis - Bitget
Esperion Acquires Enbumyst Maker Corstasis - Benzinga
Esperion to Acquire Corstasis, Expanding Heart Failure Portfolio - TipRanks
1.15%
3.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):